CURRICULUM **V**ITAE Yasufumi Katanasaka, Ph.D

Assistant Professor
Division of Molecular Medicine
Graduate School of Pharmaceutical Sciences
University of Shizuoka
52-1 Yada, Shizuoka 422-8526, Japan
Phone: +81-54-264-5766
Fax: +81-54-264-5764
E-mail: katana@u-shizuoka-ken.ac.jp

WORK EXPERIENCE

Assistant Professor, April 2010 to present
Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

Projects

- Molecular-targeted therapy of chronic heart failure by natural compounds
- Analysis of molecular mechanism by which PRMT5/MEP50 methylsome complex regulates heart failure
- Clinical studies to assess food function in lifestyle diseases

Postdoctoral fellowship, September 2016 to August 2017
Boston University School of Medicine, Boston, MA, USA

Projects

- Clonal hematopoiesis in heart failure
- Gene manipulation in hematopoietic stem cells

Postdoctoral fellowship, April 2008 to March 2010
Shien-Lab, National Cancer Center Hospital, Tokyo, Japan

Projects

- Molecular-targeted therapy of PI3K/mTOR inhibitor in lung cancer
- Analysis of molecular mechanism of EGFRvIII-induced angiogenesis in glioma
- Anti-lymphangiogenesis therapy using molecular-targeted drugs

EDUCATION

Ph.D. in Pharmaceutical Science, March 2008
Department of Medical Biochemistry, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

Dissertation title: Proteomic identification of novel angiogenesis-related proteins and

its application to antineovascular therapy

- Proteomic analysis of VEGF-activated endothelial cells using 2D-DIGE
- Molecular-targeted drug delivery using liposomes and cancer therapy

Supervisors: Prof. N. Oku and Prof. N. Ohashi

Master of Sciences in Pharmaceutical Science, March 2005

Department of Medical Biochemistry, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

Dissertation title: Proteomic analysis for identification of angiogenesis-related proteins

Supervisors: Prof. N. Oku and Prof. N. Ohashi

Bachelor of Sciences in Pharmaceutical Science, March 2003

Faculty of Pharmaceutical Science, University of Shizuoka, Shizuoka, Japan

PUBLICATIONS

1. Kawase, Y., Sunagawa, Y., Shimizu, K., Funamoto, M., Hamabe-Horiike, T., **Katanasaka, Y**., Shimizu, S., Hawke, P., Mori, K., Komiyama, M., Hasegawa, K., & Morimoto, T. (2023). 6-Shogaol, an Active Component of Ginger, Inhibits p300 Histone Acetyltransferase Activity and Attenuates the Development of Pressure-Overload-Induced Heart Failure. Nutrients, 15(9), 2232.
2. Iwashita, M., Shioi, R., Sugiyama, M., Hashizume, K., Kan, T., Naito, S., Takai, H., Kawase, Y., Hamabe-Horiike, T., **Katanasaka, Y**, Sunagawa, Y., & Morimoto, T. (2023). Monodemethylated Metabolites of Orally Administered Nobiletin: Identification and Quantitation in Rat Plasma and Tissues. Journal of Agricultural and Food Chemistry, 71(26), 10028-10036.
3. **Katanasaka, Y**, Sunagawa, Y., Miyazaki, Y., Funamoto, M., Shimizu, S., Shimizu, K., Yamakage, H., Satoh-Asahara, N., Toyama, K., Sabashi, T., Suzuki, M., Hamabe-Horiike, T., Komiyama, M., Wada, H., Mori, K., Hasegawa, K., & Morimoto, T. (2022). Ameliorating prediabetic subject status via fermented tea supplementation: A randomized, double-blind, parallel-group comparison study. Journal of Functional Foods, 97, 105257.
4. **Katanasaka, Y**, Saito, A., Sunagawa, Y., Sari, N., Funamoto, M., Shimizu, S., Shimizu, K., Akimoto, T., Ueki, C., Kitano, M., Hasegawa, K., Sakaguchi, G., & Morimoto, T. (2022). ANGPTL4 Expression Is Increased in Epicardial Adipose Tissue of Patients with Coronary Artery Disease. Journal of Clinical Medicine, 11(9), 2449.
5. Sunagawa, Y., Kawaguchi, S., Miyazaki, Y., **Katanasaka, Y**, Funamoto, M., Shimizu, K., Shimizu, S., Hamabe-Horiike, T., Kawase, Y., Komiyama, M., Mori, K., Murakami, A., Hasegawa, K., & Morimoto, T. (2022). Auraptene, a citrus peel-derived natural product, prevents myocardial infarction-induced heart failure by activating PPARα in rats. Phytomedicine, 107, 154457.
6. Sunagawa, Y., Katayama, A., Funamoto, M., Shimizu, K., Shimizu, S., Sari, N., **Katanasaka, Y** Miyazaki, Y., Hosomi, R., Hasegawa, K., & Morimoto, T. (2022). The polyunsaturated fatty acids, EPA and DHA, ameliorate myocardial infarction-induced heart failure by inhibiting p300-HAT activity in rats. The Journal of Nutritional Biochemistry, 106, 109031.
7. Shimizu, S., Sunagawa, Y., Hajika, N., Yorimitsu, N., **Katanasaka, Y**, Funamoto, M., Miyazaki, Y., Sari, N., Shimizu, K., & Hasegawa, K. (2022). Multimerization of the GATA4 transcription factor regulates transcriptional activity and cardiomyocyte hypertrophic response. International Journal of Biological Sciences, 18(3), 1079-1095.
8. Ono, M., Sunagawa, Y., Mochizuki, S., Katagiri, T., Takai, H., Iwashimizu, S., Inai, K., Funamoto, M., Shimizu, K., Shimizu, S., **Katanasaka, Y**, Komiyama, M., Hawke, P., Hara, H., Arakawa, Y., Mori, K.,

Asai, A., Hasegawa, K., & Morimoto, T. (2022). Chrysanthemum morifolium Extract Ameliorates Doxorubicin-Induced Cardiotoxicity by Decreasing Apoptosis. Cancers, 14(3), 683.

9. Mittal, S., Komiyama, M., Ozaki, Y., Yamakage, H., Satoh-Asahara, N., Yasoda, A., Wada, H., Funamoto, M., Shimizu, K., Miyazaki, Y., **Katanasaka, Y**, Sunagawa, Y., Morimoto, T., Takahashi, Y., Nakayama, T., & Hasegawa, K. (2022). Gingival bleeding and pocket depth among smokers and the related changes after short-term smoking cessation. Acta Odontologica Scandinavica, 80(4), 258-263.
10. Katagiri, T., Sunagawa, Y., Maekawa, T., Funamoto, M., Shimizu, S., Shimizu, K., **Katanasaka, Y**, Komiyama, M., Hawke, P., Hara, H., Mori, K., Hasegawa, K., & Morimoto, T. (2022). Ecklonia stolonifera Okamura Extract Suppresses Myocardial Infarction-Induced Left Ventricular Systolic Dysfunction by Inhibiting p300-HAT Activity. Nutrients, 14(3), 580.
11. Funamoto, M., Sunagawa, Y., **Katanasaka, Y**, Kato, T., Funada, J., Ajiro, Y., Komiyama, M., Akao, M., Yasoda, A., Yamakage, H., Satoh-Asahara, N., Wada, H., Ikeda, Y., Morimoto, T., & Hasegawa, K. (2022). Effects of high-absorption curcumin for the prevention of hypertensive heart disease: a double-blind, placebo-controlled, randomized clinical study. European Heart Journal Open, 2(5).
12. Funamoto, M., Sunagawa, Y., Gempei, M., Shimizu, K., **Katanasaka, Y**, Shimizu, S., Hamabe-Horiike, T., Appendino, G., Minassi, A., Koeberle, A., Komiyama, M., Mori, K., Hasegawa, K., & Morimoto, T. (2022). Pyrazole-Curcumin Suppresses Cardiomyocyte Hypertrophy by Disrupting the CDK9/CyclinT1 Complex. Pharmaceutics, 14(6), 1269.
13. Yura, Y., Miura-Yura, E., **Katanasaka, Y**, Min, K.-D., Chavkin, N., Polizio, A. H., Ogawa, H., Horitani, K., Doviak, H., Evans, M. A., Sano, M., Wang, Y., Boroviak, K., Philippos, G., Domingues, A. F., Vassiliou, G., Sano, S., & Walsh, K. (2021). The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene *Ppm1d* Promotes Inflammation and Non-Ischemic Heart Failure in Mice. Circulation Research, 129(6), 684-698.
14. Sari, N., **Katanasaka, Y (co-fitst author)**, Sugiyama, Y., Sunagawa, Y., Miyazaki, Y., Funamoto, M., Shimizu, S., Shimizu, K., Murakami, A., Mori, K., Wada, H., Hasegawa, K., & Morimoto, T. (2021). Zerumbone prevents pressure overload-induced left ventricular systolic dysfunction by inhibiting cardiac hypertrophy and fibrosis. Phytomedicine, 92, 153744.
15. Sari, N., **Katanasaka, Y**, Sugiyama, Y., Miyazaki, Y., Sunagawa, Y., Funamoto, M., Shimizu, K., Shimizu, S., Hasegawa, K., & Morimoto, T. (2021). Alpha Mangostin Derived from *Garcinia magostana* Linn Ameliorates Cardiomyocyte Hypertrophy and Fibroblast Phenotypes *in Vitro*. Biological and Pharmaceutical Bulletin, 44(10), 1465-1472.
16. **Katanasaka, Y**, Yoshida, N., Naitou, H., Naruta, R., Miyazaki, Y., Sunagawa, Y., Funamoto, M., Shimizu, K., Shimizu, S., Sari, N., Yamakage, H., Sato-Asahara, N., Hasegawa, K., & Morimoto, T. (2021). Effect of Theaflavin on Oral Bacteria in Japanese Subjects: A Randomized, Placebo-Controlled, Double-Blind Study. Journal of Medicinal Food, 24(11), 1186-1190.
17. **Katanasaka, Y**, Hirano, S., Sunagawa, Y., Miyazaki, Y., Sato, H., Funamoto, M., Shimizu, K., Shimizu, S., Sari, N., Hasegawa, K., & Morimoto, T. (2021). Clinically Administered Doses of Pitavastatin and Rosuvastatin Effects on Myocardial Hypertrophy Using Cultured Cardiomyocytes. International Heart Journal, 62(6), 1379-1386.
18. Sunagawa, Y., Shimizu, K., Katayama, A., Funamoto, M., Shimizu, K., Nurmila, S., Shimizu, S., Miyazaki, Y., **Katanasaka, Y**, & Hasegawa, K. (2021). Metformin suppresses phenylephrine-induced hypertrophic responses by inhibiting p300-HAT activity in cardiomyocytes. J Pharmacol Sci, 147(2), 169-175.
19. Sunagawa, Y., Miyazaki, Y., Funamoto, M., Shimizu, K., Shimizu, S., Nurmila, S., **Katanasaka, Y**, Ito, M., Ogawa, T., & Ozawa-Umeta, H. (2021). A novel amorphous preparation improved curcumin bioavailability in healthy volunteers: A single-dose, double-blind, two-way crossover study. Journal of Functional Foods, 81, 104443.

20. Sunagawa, Y., Funamoto, M., Shimizu, K., Shimizu, S., Sari, N., **Katanasaka, Y**, Miyazaki, Y., Kakeya, H., Hasegawa, K., & Morimoto, T. (2021). Curcumin, an Inhibitor of p300-HAT Activity, Suppresses the Development of Hypertension-Induced Left Ventricular Hypertrophy with Preserved Ejection Fraction in Dahl Rats. Nutrients, 13(8), 2608.
21. Shimizu, K., Sunagawa, Y., Funamoto, M., Honda, H., **Katanasaka, Y**, Murai, N., Kawase, Y., Hirako, Y., Katagiri, T., Yabe, H., Shimizu, S., Sari, N., Wada, H., Hasegawa, K., & Morimoto, T. (2021). The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2;GATA4 Signaling Pathway. Pharmaceuticals, 14(12), 1268.
22. Mittal, S., Komiyama, M., Ozaki, Y., Yamakage, H., Satoh-Asahara, N., Yasoda, A., Wada, H., Funamoto, M., Shimizu, K., Miyazaki, Y., **Katanasaka, Y**, Sunagawa, Y., Morimoto, T., Takahashi, Y., Nakayama, T., & Hasegawa, K. (2021). Gingival bleeding and pocket depth among smokers and the related changes after short-term smoking cessation. Acta Odontologica Scandinavica, 1-6.
23. Komiyama, M., Ozaki, Y., Miyazaki, Y., **Katanasaka, Y**, Sunagawa, Y., Funamoto, M., Shimizu, K., Yamakage, H., Sato-Asahara, N., & Yasoda, A. (2021). Neutrophil/lymphocyte ratio is correlated with levels of inflammatory markers and is significantly reduced by smoking cessation. Journal of International Medical Research, 49(6), 03000605211019223.
24. Funamoto, M., Sunagawa, Y., **Katanasaka, Y**, Shimizu, K., Miyazaki, Y., Sari, N., Shimizu, S., Mori, K., Wada, H., Hasegawa, K., & Morimoto, T. (2021). Histone Acetylation Domains Are Differentially Induced during Development of Heart Failure in Dahl Salt-Sensitive Rats. International journal of molecular sciences, 22(4), 1771.
25. Shimizu, K., Sunagawa, Y., Funamoto, M., Wakabayashi, H., Genpei, M., Miyazaki, Y., **Katanasaka, Y**, Sari, N., Shimizu, S., Katayama, A., Shibata, H., Iwabuchi, Y., Kakeya, H., Wada, H., Hasegawa, K., & Morimoto, T. (2020). The Synthetic Curcumin Analogue GO-Y030 Effectively Suppresses the Development of Pressure Overload-induced Heart Failure in Mice. Sci Rep, 10(1), 7172.
26. Sari, N., **Katanasaka, Y**, Honda, H., Miyazaki, Y., Sunagawa, Y., Funamoto, M., Shimizu, K., Shimizu, S., Wada, H., Hasegawa, K., & Morimoto, T. (2020). Cacao Bean Polyphenols Inhibit Cardiac Hypertrophy and Systolic Dysfunction in Pressure Overload-induced Heart Failure Model Mice. Planta Medica, 86(17), 1304-1312.
27. Miyazaki, Y., **Katanasaka, Y (co-first author)**, Tsutsui, Y., Sunagawa, Y., Funamoto, M., Shimizu, K., Shimizu, S., Sari, N., Yamakage, H., Satoh-Asahara, N., Toyama, K., Suzuki, M., Shimizu, A., Wada, H., Hasegawa, K., & Morimoto, T. (2020). A Randomized Placebo-controlled, Double-blind Study of Kosen-cha, a Polymerized Catechin-rich Green Tea, for Obesity in Pre-obese Japanese Subjects. BPB Reports, 3(6), 202-207.
28. **Katanasaka, Y**, Miyazaki, Y., Sunagawa, Y., Funamoto, M., Shimizu, K., Shimizu, S., Sari, N., Shimizu, Y., Wada, H., Hasegawa, K., & Morimoto, T. (2020). Kosen-cha, a Polymerized Catechin-Rich Green Tea, as a Potential Functional Beverage for the Reduction of Body Weight and Cardiovascular Risk Factors: A Pilot Study in Obese Patients. Biol Pharm Bull, 43(4), 675-681.
29. Wang, Y., Sano, S., Oshima, K., Sano, M., Watanabe, Y., **Katanasaka, Y**, Yura, Y., Jung, C., Anzai, A., Swirski, F. K., Gokce, N., & Walsh, K. (2019). Wnt5a-Mediated Neutrophil Recruitment Has an Obligatory Role in Pressure Overload-Induced Cardiac Dysfunction. Circulation, 140(6), 487-499.
30. Sano, S., Wang, Y., Yura, Y., Sano, M., Oshima, K., Yang, Y., **Katanasaka, Y**, Min, K. D., Matsuura, S., Ravid, K., Mohi, G., & Walsh, K. (2019). JAK2 (V617F) -Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine Heart Failure. JACC Basic Transl Sci, 4(6), 684-697.
31. Funamoto, M., Shimizu, K., Sunagawa, Y., **Katanasaka, Y**, Miyazaki, Y., Kakeya, H., Yamakage, H., Satoh-Asahara, N., Wada, H., Hasegawa, K., & Morimoto, T. (2019). Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus. J Diabetes Res, 2019, 8208237.

32. Sunagawa, Y., Okamura, N., Miyazaki, Y., Shimizu, K., Genpei, M., Funamoto, M., Shimizu, S., **Katanasaka, Y**, Morimoto, E., Yamakage, H., Komiyama, M., Satoh-Asahara, N., Wada, H., Suzuki, M., Hasegawa, K., & Morimoto, T. (2018). Effects of Products Containing Bacillus subtilis var. natto on Healthy Subjects with Neck and Shoulder Stiffness, a Double-Blind, Placebo-Controlled, Randomized Crossover Study. Biol Pharm Bull, 41(4), 504-509.
33. Sunagawa, Y., Funamoto, M., Sono, S., Shimizu, K., Shimizu, S., Genpei, M., Miyazaki, Y., **Katanasaka, Y**, Morimoto, E., Ueno, M., Komiyama, M., Kakeya, H., Wada, H., Hasegawa, K., & Morimoto, T. (2018). Curcumin and its demethoxy derivatives possess p300 HAT inhibitory activity and suppress hypertrophic responses in cardiomyocytes. J Pharmacol Sci, 136(4), 212-217.
34. Sano, S., Oshima, K., Wang, Y., MacLauchlan, S., **Katanasaka, Y**, Sano, M., Zuriaga, M. A., Yoshiyama, M., Goukassian, D., Cooper, M. A., Fuster, J. J., & Walsh, K. (2018). Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1beta/NLRP3 Inflammasome. Journal of the American College of Cardiology, 71(8), 875-886.
35. Sano, S., Oshima, K., Wang, Y., **Katanasaka, Y**, Sano, M., & Walsh, K. (2018). CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease. Circulation Research, 123(3), 335-341.
36. Suzuki, H., **Katanasaka, Y,** Sunagawa, Y., Miyazaki, Y., Funamoto, M., Wada, H., Hasegawa, K., & Morimoto, T. (2016). Tyrosine phosphorylation of RACK1 triggers cardiomyocyte hypertrophy by regulating the interaction between p300 and GATA4. Biochimica et Biophysica Acta, 1862(9), 1544-1557.
37. Sunagawa, Y., **Katanasaka, Y**, Wada, H., Hasegawa, K., & Morimoto, T. (2016). Functional Analysis of GATA4 Complex, a Cardiac Hypertrophy-response Transcriptional Factor, Using a Proteomics Approach. Yakugaku Zasshi. Journal of the Pharmaceutical Society of Japan, 136(2), 151-156.
38. Nakamura K, Sano S, Fuster JJ, Kikuchi R, Shimizu I, Ohshima K, **Katanasaka Y**, Ouchi N, Walsh K. Secreted frizzled-related protein 5 diminishes cardiac inflammation and protects the heart from ischemia-reperfusion injury. *J Biol Chem*. 2016;**291**:2566-2575.
39. Sunagawa Y, **Katanasaka Y**, Wada H, Hasegawa K, Morimoto T. Functional Analysis of GATA4 Complex, a Cardiac Hypertrophy-response Transcriptional Factor, Using a Proteomics Approach. *Yakugaku Zasshi*. 2016;**136**:151-156.
40. Morimoto T, **Katanasaka Y**, Sunagawa Y, Hirano S, Miyazaki Y, Funamoto M, Hojo Y, Suzuki H, Morimoto E, Ueno M, Shimatsu A, Satoh-Asahara N, Yamakage H, Wada H, Hasegawa K. Effects of statins on left ventricular diastolic function in patients with dyslipidemia and diastolic dysfunction (STAT-LVDF study). *Biol Pharm Bull*. 2015;**38**:1404-1409
41. Sunagawa Y, Hirano S, **Katanasaka Y**, Miyazaki Y, Funamoto M, Okamura N, Hojo Y, Suzuki H, Doi O, Yokoji T, Morimoto E, Takahashi T, Ozawa H, Imaizumi A, Ueno M, Kakeya H, Shimatsu A, Wada H, Hasegawa K, Morimoto T. Colloidal submicron-particle curcumin exhibits high absorption efficiency-a double-blind, 3-way crossover study. Journal of nutritional science and vitaminology. 2015;**61**:37-44
42. Kikuchi R, Nakamura K, MacLauchlan S, Ngo D, Shimizu I, Fuster J, **Katanasaka Y**, et al: An anti-angiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease. *Nature Medicine*. 2014;**20**:1464-1471
43. Sunagawa Y, Sono S, **Katanasaka Y**, et al. Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats. *J Pharmacol Sci*. 2014;**126**:329-336.
44. **Katanasaka Y**, et al: Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines. *Cancer Lett.* **347**:196-203, 2014.
45. **Katanasaka Y**, et al. Epidermal growth factor receptor variant type iii markedly accelerates

angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma. *Molecular cancer;* **12**:31, 2013

46. **Katanasaka Y**, et al. Application of curcumin to heart failure therapy. *Biol Pharm Bull*; **36**: 13-17, 2013.
47. Sugiyama T, Asai T, Nedachi YM, **Katanasaka Y**, et al: Enhanced active targeting via cooperative binding of ligands on liposomes to target receptors. *PLoS One*; **8**:e67550, 2013.
48. Morimoto T, Sunagawa Y, **Katanasaka Y**, et al.: Drinkable preparation of Theracurmin exhibits high absorption efficiency--a single-dose, double-blind, 4-way crossover study. *Biol Pharm Bull*.; **36**: 1708-14. 2013
49. Yunokawa M, Koizumi F, Kitamura Y, **Katanasaka Y**, et al, Tamura K. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. *Cancer Sci*; **103**:1665-71, 2012.
50. Sunagawa Y, Wada H, Suzuki H, Sasaki H, Imaizumi A, Fukuda H, Hashimoto T, **Katanasaka Y**, et al. A novel drug delivery system of oral curcumin markedly improves efficacy of treatment for heart failure after myocardial infarction in rats. *Biol Pharm Bull*; **35**:139-44, 2012
51. Kodera Y, **Katanasaka Y**, et al, Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. *Breast Cancer Res*; **13**:R66, 2011.
52. Sunagawa Y, Morimoto T, Wada H, Takaya T, **Katanasaka Y**, et al. A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin converting enzyme inhibitor exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. *Circ J*; **75**:2151-9, 2011.
53. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, **Katanasaka Y**, et al. Innovative preparation of curcumin for improved oral bioavailability, *Biol Pharm Bull*; **34**:660-5, 2011.
54. Taguchi F, Kodera Y, **Katanasaka Y**, et al. Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. *Invest New Drugs*; **29**:660-5, 2011.
55. **Katanasaka Y**, Ishii T, Asai T, Naitou H, Maeda N, Koizumi F, Miyagawa S, Ohashi N, and Oku N. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78. *Int J Cancer*; **127**:2685-98, 2010.
56. Murase Y, Asai T, **Katanasaka Y**, Sugiyama T, Shimizu K, Maeda N, and Oku N. A novel DDS strategy, "dual-targeting", and its application for antineovascular therapy. *Cancer Lett*; **287**:165-71, 2010.
57. **Katanasaka Y**, Ida T, Asai T, Maeda N, and Oku N. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes. *Int J Pharm*; **360**:219-24, 2008.
58. **Katanasaka Y**, Ida T, Asai T, Shimizu K, Koizumi F, Maeda N, Baba K, and Oku N. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416. *Cancer Lett*; **270**:260-68, 2008.
59. Asai T, Miyazawa S, Maeda N, Hatanaka K, **Katanasaka Y**, Shimizu K, Shuto S, and Oku N. Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC. *Cancer Sci*; **99**:1029-33, 2008.
60. Asai T, Suzuki Y, Matsushita S, Yonezawa S, Yokota J, **Katanasaka Y**, Ishida T, Dewa T, Kiwada H, Nango M, and Oku N. Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown. *Biochem Biophys Res Commun*; **368**:243-8, 2008.
61. **Katanasaka Y**, Asai T, Naitou H, Ohashi N, and Oku N. Proteomic characterization of angiogenic endothelial cells stimulated with cancer cell-conditioned medium. *Biol Pharm Bull*; 30:2300-7, 2007.
62. Kondo M, Asai T, **Katanasaka Y**, Sadzuka Y, Tsukada H, Ogino K, Taki T, Baba K, and Oku N. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. *Int*

J Cancer; **108**:301-6, 2004.

CHAPTERS IN BOOKS

1. **Katanasaka, Y**. (2017). [Development of Targeted Pharmacotherapy for Cardiovascular Disease]. Yakugaku Zasshi. Journal of the Pharmaceutical Society of Japan, 137(11), 1349-1353.
2. **Katanasaka Y** and Morimoto T. Green tea in antiaging. In *Antiaging medicine*, p.23-27. Tokyo: Medical view, ISBN: 9784815917425. (In Japanese), 2015.
3. **Katanasaka Y** and N. Oku. Integrin. In *Liver Metastasis*, M. Monden and N. Matsuura,eds., p. 23-27. Tokyo: Nagai Syoten, ISBN: 9784815917425. (In Japanese), 2005.

GRANTS & AWARDS

1. Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research(C) 19K07325, 2019-2021
2. Effect of a tea component Theaflavin on oral flora, JST A-STEP, 18088769, 2018 -2019
3. Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientist 16K18876, 2016-2018
4. Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientist 25860052, 2013-2015
5. Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientist (Start-up) 22890153, 2010-2011
6. The Sapporo Bioscience Foundation, 2023
7. The Takeda Science Foundation, 2022-2024
8. The Tojuro Iijima Foundation for Food Science and Technology, 2022 年
9. The Nakatomi Foundation, 2022-2023
10. he SENSHIN Medical Research Foundation, 2021-2022
11. The Mochida Memorial Foundation for Medical and Pharmaceutical Research, 2018-2019
12. The Hamamatsu Foundation for Science and Technology Promotion, 2018
13. Shizuoka city, 2018-2023 年
14. The Consortium of Universities & Local Communities in Shizuoka, 2018
15. the MSD Life Science Foundation, 2018-2019
16. The Kobayashi Foundation, 2018-2020
17. The Kanae Foundation for the Promotion of Medical Science, 2017
18. The Takeda Science Foundation, 2017
19. The Hamamatsu Foundation for Science and Technology Promotion, grant number 15-556. 2016
20. The Suzuken Memorial Foundation, 2016
21. The Tokyo Biochemistry Foundation, 2016
22. YOKOYAMA Foundation for Clinical Pharmacology, 2015

1. Young Investigator Award, Japanese Society of Pharmaceutical Sciences, 2016.
2. Poster Award, 1st Japan ISCP, Kyoto, Japan, 2015.
3. Poster Award, 18th ISCP, Roma, Italy, 2013.
4. Young Investigator Award, 7th China-Japan Cardiovascular Forum, 2010.

5. Poster Award, 11th Shizuoka Forum on Health and Longevity, Shizuoka, Japan, 2006.